Ipca Labs Q4 Review - Swapping Lower Sales Growth With Better Core Margin: Prabhudas Lilladher

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Prabhudas Lilladher Report

Ipca Laboratories Ltd.'s Q4 FY21 revenue missed our estimates, mainly due to weak performance of India formulations, lower chloroquine phosphate/ hydroxychloroquine sales and steep decline in Europe generic and malaria-tender business.

With one-off benefits of Rs 3.7 billion from sales of chloroquine phosphate/ hydroxychloroquine in FY21, the company lowered its sales growth guidance of 9-10% in FY22E with-

1. India formulations at 16-18%,

2. active pharmaceutical ingredient at 5-10%,

3. export generics at 5%

4. global tender business at 5% while

5. branded generics at 13-15%.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.